Over the past decade, the emergence of effective immunotherapies has revolutionized the
clinical management of many types of cancers. However, long-term durable tumour control …

Abstract p53, which is encoded by the most frequently mutated gene in cancer, TP53, is an
attractive target for novel cancer therapies. Despite major challenges associated with this …

The accurate selection of neoantigens that bind to class I human leukocyte antigen (HLA)
and are recognized by autologous T cells is a crucial step in many cancer immunotherapy …

Systemic pan-tumor analyses may reveal the significance of common features implicated in
cancer immunogenicity and patient survival. Here, we provide a comprehensive multi-omics …

Control interventions steer the evolution of molecules, viruses, microorganisms or other cells
towards a desired outcome. Applications range from engineering biomolecules and …

Immunotherapy has emerged as a crucial strategy to combat cancer by “reprogramming” a
patient's own immune system. Although immunotherapy is typically reserved for patients with …

Abstract p53 mutations predispose cancer cell development, promote their survival and
metastasis, and lead to ineffective therapeutic responses and unfavorable prognosis. No …

Summary p53 was discovered 45 years ago as an SV40 large T antigen binding protein,
coded by the most frequently mutated TP53 gene in human cancers. As a transcription …

The majority of JAK2V617F-negative myeloproliferative neoplasms (MPNs) have disease-
initiating frameshift mutations in calreticulin (CALR), resulting in a common carboxyl-terminal …

Intratumor heterogeneity (ITH) is associated with tumor progression in several clinical and
experimental settings and contributes to therapeutic resistance. Its relation to cancer …